Welcome to our dedicated page for Summit Therapeutics SEC filings (Ticker: SMMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Summit Therapeutics Inc. (SMMT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. Summit is a Delaware-incorporated biopharmaceutical oncology company listed on The Nasdaq Stock Market LLC, and its filings offer detailed information on clinical progress, financing activities, and material agreements.
Among the key documents are Form 8-K current reports, where Summit has described material events such as private placements of common stock, amendments to its at-the-market distribution agreement, and clinical and scientific updates related to ivonescimab. For example, the company filed 8-Ks summarizing Akeso’s Phase III HARMONi-A results in EGFR-mutated NSCLC, including overall survival hazard ratios and median survival data for ivonescimab plus chemotherapy versus chemotherapy alone, and reporting presentations of HARMONi data at major oncology conferences.
Other 8-K filings detail Summit’s entry into securities purchase agreements for a significant private placement of common stock to institutional and individual investors, including insiders and Akeso, and amendments to its distribution agreement with a sales agent to expand its at-the-market equity offering capacity. Filings also cover operational matters such as a sub-sublease for office space in Palo Alto, California, and inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
Investors can also review references to Summit’s shelf registration on Form S-3 and related prospectus supplements that support its at-the-market program, as cited in the company’s 8-K disclosures. These filings help explain how Summit finances its global Phase III development program for ivonescimab and other corporate initiatives.
On Stock Titan, each new Summit filing is captured from EDGAR and paired with AI-powered summaries that highlight the main points, such as clinical trial outcomes, capital-raising terms, and key contractual provisions. Users can quickly understand the implications of a filing without reading the full legal text, while still having direct access to the original documents for deeper analysis.
Summit Therapeutics (SMMT) Co‑CEO, director, and 10% owner Robert W. Duggan reported acquisitions of common stock. He acquired 13,980,789 shares at $18.74 in a private placement pursuant to a definitive agreement dated October 21, 2025, anticipated to close on or about October 23, 2025. He also acquired 266,808 shares indirectly at $18.74 and purchased 26,680 shares at $18.74.
Following these transactions, he beneficially owned 570,073,879 shares directly and 25,724,474 shares indirectly via a trust, with additional indirect holdings of 76,680, 31,000, and 10,199,776 shares through family and related trusts.
Summit Therapeutics (SMMT) Co‑Chief Executive Officer and director Mahkam Zanganeh, a 10% owner, reported multiple share purchases dated 10/21/2025 tied to a private placement at $18.74 per share. Reported acquisitions include 266,808 shares by the Mahkam Zanganeh Revocable Trust, 26,680 shares for an immediate family member, and 13,980,789 shares by her spouse. The filing notes the transaction was pursuant to a definitive agreement and is anticipated to close on or about October 23, 2025. The report includes a standard disclaimer of beneficial ownership for certain indirect holdings.
Summit Therapeutics Inc. announced a private placement of 26,682,846 shares of common stock at $18.74 per share, matching the October 21, 2025 closing price, for aggregate gross proceeds of approximately $500.0 million. The financing is a primary issuance and is expected to close on or before October 28, 2025, subject to customary closing conditions.
Company leaders and employees participated, purchasing an aggregate of 14,514,402 shares, and Akeso, Inc. purchased 533,617 shares. The shares are being issued in reliance on Section 4(a)(2) and Regulation D exemptions. Summit agreed to file a registration statement to register the resale of these shares as soon as reasonably practicable and no later than December 19, 2025, and to use reasonable best efforts to have it declared effective.
Summit Therapeutics Inc. filed a Form 4 disclosing an equity award to Anand Bhaskar, the company's Chief Accounting Officer. On 09/18/2025 Mr. Bhaskar was granted a stock option to purchase 50,000 shares of common stock at an exercise price of $19.23 per share.
The option vests in four equal annual installments with the first vesting on 09/18/2026 and expires on 09/18/2035. After the grant, Mr. Bhaskar beneficially owns 50,000 underlying shares directly. The Form 4 was signed on 09/19/2025.
Summit Therapeutics Inc. (SMMT) Form 4 filing shows insider transactions by Mahkam Zanganeh, who is identified as Co-Chief Executive Officer, a Director and a 10% owner. On 09/10/2025 the reporting person purchased 333,394 shares of common stock at a weighted average price of $17.68 per share. On 09/11/2025 an additional 5,000 shares were purchased at $18.07 per share. The filing also reports a disposition of 31,000 shares and lists significant indirect holdings through trusts and a spouse, while the reporting person disclaims beneficial ownership of certain reported securities except for any pecuniary interest.
Robert W. Duggan, Co-Chief Executive Officer and Director of Summit Therapeutics Inc. (SMMT), reported purchases of the company's common stock on September 10 and 11, 2025. On 09/10/2025 he purchased 333,394 shares at a weighted-average price of $17.68 per share, and on 09/11/2025 he purchased 5,000 shares at $18.07 per share. Following the reported transactions, the filing lists 556,093,090 shares as beneficially owned directly by the reporting person. The filing also discloses several indirect holdings associated with the reporting person, including 31,000 shares held by a spouse and multi-million share interests held through trusts with the spouse as trustee (10,199,776 and 25,457,666 shares).
Summit Therapeutics Inc. filed a current report to note that it issued a press release on September 7, 2025 announcing ivonescimab data from its global Phase III HARMONi clinical trial. The data were presented the same day during the Presidential Symposium at the International Association for the Study of Lung Cancer’s 2025 World Conference on Lung Cancer by Jonathan Goldman, MD of UCLA.
The company plans to discuss the ivonescimab HARMONi data on a conference call scheduled for 8:00 a.m. ET on September 8, 2025. The press release is furnished as Exhibit 99.1 and the accompanying presentation slides for the conference call are furnished as Exhibit 99.2.
Summit Therapeutics Inc. disclosed that it furnished a press release announcing its financial results and operational progress for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02.
The filing clarifies that the exhibit is being furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into other Securities Act or Exchange Act filings except by specific reference. The company’s common stock trades under the ticker SMMT on The Nasdaq Stock Market.
Summit Therapeutics amended its distribution agreement with J.P. Morgan Securities LLC to expand its at-the-market capacity, increasing the aggregate amount of common stock it may sell by $360,000,000. The company previously filed a prospectus supplement covering up to $90.0 million of sales, with approximately $45.8 million remaining available under that supplement.
The amendment permits the Sales Agent to sell shares from time to time, including on Nasdaq, to market makers, in block or negotiated transactions, or by other lawful methods, and the Sales Agent will receive a commission of up to 3.0% of gross proceeds. The company is not obligated to sell any shares; any issuance would be pursuant to its effective Form S-3 registration statement and the related prospectus supplements.
Summit Therapeutics Inc. is offering up to $360,000,000 of common stock via an amendment to its distribution agreement with J.P. Morgan, expanding available at-the-market sales; the Sales Agent may earn up to 3.0% commission and sales will occur on Nasdaq under the symbol SMMT (closing price $28.66 on August 8, 2025).
The company’s lead program, ivonescimab (a PD-1/VEGF bispecific licensed from Akeso), produced positive Phase III results: the multiregional HARMONi topline showed a statistically significant PFS benefit (HR 0.52; 95% CI 0.41–0.66; p<0.00001) and an OS trend (HR 0.79; p=0.057). Akeso-sponsored trials and Chinese approvals were also reported. Summit paid upfront consideration under the license (including $474.9M cash plus 10M shares and a subsequent $15M territorial amendment).
Material financials and risks disclosed include a noted substantial doubt about going concern, net tangible book value of approximately $257.4M ($0.35 per share) as of June 30, 2025, and projected as-adjusted net tangible book value of $611.7M ($0.81 per share) after the illustrative sale—producing $27.85 per-share dilution to new investors. Outstanding shares and option pools are also substantial.
FAQ
What is the current stock price of Summit Therapeutics (SMMT)?
What is the market cap of Summit Therapeutics (SMMT)?
